-
平臺編號：bio-69602
-
國際編號：CRL-5819?
-
細胞信息： NCI-H1404
-
規(guī)格：Frozen
-
用途：ATCC原裝細胞
-
服務(wù)費用：
加載中…… - 訂購
-
注意事項：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準）
NCI-H1404
年限：48 years
運輸方式：凍存運輸
器官來源：肺
數(shù)量：大量
生長狀態(tài)：懸浮生長，多細胞聚集
ATCC Number：CRL-5819?
相關(guān)疾?。浩渌膊?br /> 是否是腫瘤細胞：1
物種來源：人
細胞形態(tài)：上皮樣
規(guī)格：100 ul Designations: NCI-H1404 [H1404]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Disease: papillary adenocarcinoma
Derived from metastatic site: lymph node
Cellular Products:surfactant associated protein A (SP-A); surfactant associated protein B (SP-B)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Tumorigenic:Yes
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 9,14
D16S539: 12
D5S818: 12
D7S820: 11,14
THO1: 7,9.3
TPOX: 9,11
vWA: 19
Age: 48 years
Gender: male
Ethnicity: Caucasian
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy.
Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.
The cells express protein and RNA of SP-A, the major surfactant associated protein, and SP-B.
SP-C RNA was not expressed.
Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)
The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 10% fetal bovine serum and 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
References: 23081: Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
運輸方式：凍存運輸
器官來源：肺
數(shù)量：大量
生長狀態(tài)：懸浮生長，多細胞聚集
ATCC Number：CRL-5819?
相關(guān)疾?。浩渌膊?br /> 是否是腫瘤細胞：1
物種來源：人
細胞形態(tài)：上皮樣
規(guī)格：100 ul Designations: NCI-H1404 [H1404]
Depositors: ?AF Gazdar, JD Minna
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:suspension, multicell aggregates
Organism: Homo sapiens
Morphology:epithelial
Source: Organ: lung
Disease: papillary adenocarcinoma
Derived from metastatic site: lymph node
Cellular Products:surfactant associated protein A (SP-A); surfactant associated protein B (SP-B)
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions:The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Tumorigenic:Yes
DNA Profile (STR):Amelogenin: X
CSF1PO: 10
D13S317: 9,14
D16S539: 12
D5S818: 12
D7S820: 11,14
THO1: 7,9.3
TPOX: 9,11
vWA: 19
Age: 48 years
Gender: male
Ethnicity: Caucasian
Comments:This line was derived by A.F. Gazdar, H.K. Oie, J.D. Minna and associates from a lymph node metastasis obtained from a patient prior to therapy.
Ultrastructural studies demonstrated the presence of cytoplasmic structures characteristic of Clara cells.
The cells express protein and RNA of SP-A, the major surfactant associated protein, and SP-B.
SP-C RNA was not expressed.
Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)
The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
- 0.02 mg/ml insulin
- 0.01 mg/ml transferrin
- 25 nM sodium selenite (final conc.)
- 50 nM Hydrocortisone (final conc.)
- 1 ng/ml Epidermal Growth Factor (do not filter)
- 0.01 mM ethanolamine (final conc.)
- 0.01 mM phosphorylethanolamine (final conc.)
- 100 pM triiodothyronine (final conc.)
- 0.5% (w/v) bovine serum albumin (final conc.)
- 0.5 mM sodium pyruvate (final conc.)
- extra 2mM L-glutamine (for final conc. of 4.5mM)
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol: Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 10% fetal bovine serum and 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
References: 23081: Gazdar AF, et al. Peripheral airway cell differentiation in human lung cancer cell lines. Cancer Res. 50: 5481-5487, 1990. PubMed: 2386953
23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
